The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Study Type – Therapy (case series)Level of Evidence 4What’s known on the subject? and What does the study add?It is now recognized that all patients with mRCC will eventually become resistant to VEGF inhibition. Although existing level 1 evidence supports the use of second‐line therapy, the oral mTOR inhibitor Everolimus, recent data also indicates that sequential VEGF inhibition is an appropriate...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.